Effect of nitric-oxide synthesis on tumour blood volume and vascular activity: a phase I study.
暂无分享,去创建一个
Vicky Goh | V. Goh | Q. Ng | P. Hoskin | M. Stratford | G. Tozer | L. Folkes | Peter J Hoskin | M. Saunders | Quan-Sing Ng | Michele I Saunders | Gillian M Tozer | Jessica Milner | Michael R Stratford | Lisa K Folkes | J. Milner
[1] K. Miles,et al. Perfusion CT for the assessment of tumour vascularity: which protocol? , 2003, The British journal of radiology.
[2] C. Crone,et al. THE PERMEABILITY OF CAPILLARIES IN VARIOUS ORGANS AS DETERMINED BY USE OF THE 'INDICATOR DIFFUSION' METHOD. , 1963, Acta physiologica Scandinavica.
[3] H L Fung,et al. Reversed-phase high-performance liquid chromatography method for the analysis of nitro-arginine in rat plasma and urine. , 1996, Journal of chromatography. B, Biomedical applications.
[4] S. Moncada,et al. Nitric oxide: physiology, pathophysiology, and pharmacology. , 1991, Pharmacological reviews.
[5] K. Miles,et al. CT measurement of perfusion and permeability within lymphoma masses and its ability to assess grade, activity, and chemotherapeutic response. , 1999, Journal of computer assisted tomography.
[6] C. Harvey,et al. Imaging of tumour therapy responses by dynamic CT. , 1999, European journal of radiology.
[7] Katherine W Ferrara,et al. Quantitative Evaluation of Perfusion and Permeability of Peripheral Tumors Using Contrast-Enhanced Computed Tomography , 2004, Investigative radiology.
[8] H. Fichte,et al. Quantitative assessment of lung cancer perfusion using MDCT: does measurement reproducibility improve with greater tumor volume coverage? , 2006, AJR. American journal of roentgenology.
[9] P. Kubes,et al. Nitric oxide: an endogenous modulator of leukocyte adhesion. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[10] R. Groszmann,et al. Selective inhibition of tumor microvascular permeability by cavtratin blocks tumor progression in mice. , 2003, Cancer cell.
[11] L. Ellis,et al. Roles of Nitric Oxide Synthase Inhibition and Vascular Endothelial Growth Factor Receptor-2 Inhibition on Vascular Morphology and Function in an In vivo Model of Pancreatic Cancer , 2006, Clinical Cancer Research.
[12] Y. Soini,et al. Inducible nitric oxide synthase expression, apoptosis, and angiogenesis in in situ and invasive breast carcinomas. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[13] Ernst Klotz,et al. Lung cancer perfusion at multi-detector row CT: reproducibility of whole tumor quantitative measurements. , 2006, Radiology.
[14] V. Steele,et al. Is inducible nitric oxide synthase a target for chemoprevention? , 2003, Molecular cancer therapeutics.
[15] Richard Graham Knowles,et al. Nitric oxide synthase activity in human gynecological cancer. , 1994, Cancer research.
[16] V. Goh,et al. Quantitative assessment of tissue perfusion using MDCT: comparison of colorectal cancer and skeletal muscle measurement reproducibility. , 2006, AJR. American journal of roentgenology.
[17] Fabian Kiessling,et al. Perfusion CT in patients with advanced bronchial carcinomas: a novel chance for characterization and treatment monitoring? , 2004, European Radiology.
[18] K. Aldape,et al. Expression of nitric oxide synthase in human central nervous system tumors. , 1995, Cancer research.
[19] J. Griffiths,et al. Effects of overexpression of dimethylarginine dimethylaminohydrolase on tumor angiogenesis assessed by susceptibility magnetic resonance imaging. , 2003, Cancer research.
[20] P Rhodes,et al. Roles of nitric oxide in tumor growth. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[21] R. Jain,et al. The role of nitric oxide in tumour progression , 2006, Nature Reviews Cancer.
[22] M. Jinzaki,et al. Double-Phase Helical CT of Small Renal Parenchymal Neoplasms: Correlation with Pathologic Findings and Tumor Angiogenesis , 2000, Journal of computer assisted tomography.
[23] Yoshiya Tanaka,et al. Nitric Oxide Synthase Activity in Human Lung Cancer , 1997, Japanese journal of cancer research : Gann.
[24] P K Lala,et al. Role of nitric oxide in carcinogenesis and tumour progression. , 2001, The Lancet. Oncology.
[25] R. Jain,et al. Role of nitric oxide in tumor microcirculation. Blood flow, vascular permeability, and leukocyte-endothelial interactions. , 1997, The American journal of pathology.
[26] B. Carey,et al. Quantitative Imaging in Oncology , 1996 .
[27] R Bicknell,et al. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. , 1997, The Journal of clinical investigation.
[28] H. Peterson. Modification of tumour blood flow--a review. , 1991, International journal of radiation biology.
[29] G. Tozer,et al. Inhibition of nitric oxide synthase induces a selective reduction in tumor blood flow that is reversible with L-arginine. , 1997, Cancer research.
[30] P. K. Lala,et al. NG-nitro-L-arginine methyl ester, an inhibitor of nitric oxide synthesis, ameliorates interleukin 2-induced capillary leakage and reduces tumour growth in adenocarcinoma-bearing mice. , 1996, British Journal of Cancer.
[31] E. Masini,et al. Role of nitric oxide in angiogenesis and tumor progression in head and neck cancer. , 1998, Journal of the National Cancer Institute.
[32] J. Lorente,et al. L‐arginine pathway in the sepsis syndrome , 1993, Critical care medicine.
[33] T. Veikkola,et al. Regulation of angiogenesis via vascular endothelial growth factor receptors. , 2000, Cancer research.
[34] Kazuo Miyasaka,et al. Lung Tumors Evaluated With FDG-PET and Dynamic CT: The Relationship Between Vascular Density and Glucose Metabolism , 2002, Journal of computer assisted tomography.
[35] U. Engelmann,et al. Selective expression of inducible nitric oxide synthase in human prostate carcinoma , 1998, Cancer.
[36] R K Jain,et al. Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. , 1990, Cancer research.
[37] S. Mukherji,et al. Correlation between initial and early follow-up CT perfusion parameters with endoscopic tumor response in patients with advanced squamous cell carcinomas of the oropharynx treated with organ-preservation therapy. , 2006, AJNR. American journal of neuroradiology.
[38] C. Yi,et al. Solitary pulmonary nodules: dynamic enhanced multi-detector row CT study and comparison with vascular endothelial growth factor and microvessel density. , 2004, Radiology.
[39] E. M. Renkin. Transport of potassium-42 from blood to tissue in isolated mammalian skeletal muscles. , 1959, The American journal of physiology.
[40] R K Jain,et al. Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[41] G. Garcı́a-Cardeña,et al. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. , 1997, The Journal of clinical investigation.
[42] Ricky T. Tong,et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer , 2004, Nature Medicine.
[43] D. Webb,et al. Inhibition of nitric oxide synthesis increases blood pressure in healthy humans , 1993, Journal of hypertension.
[44] C. Harris,et al. Nitric oxide in cancer and chemoprevention. , 2003, Free radical biology & medicine.
[45] C. Cooper,et al. Nitric oxide synthases: structure, function and inhibition , 2001 .
[46] P. Huang,et al. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. , 1998, The Journal of clinical investigation.